Every 10-Q that Orchestra BioMed Holdings, Inc. (OBIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OBIO filings page.
Orchestra BioMed Holdings, Inc. reported minimal revenue and higher losses while strengthening its cash position for the quarter ended June 30, 2026. Total revenue for the six months was $0.2 million, down from $1.7 million a year earlier as prior partnership revenue ended and product sales remained modest. Net loss widened to $44.4 million from $38.1 million, driven primarily by increased research and development spending related to its flagship AVIM Therapy and Virtue SAB programs.
Liquidity is supported by cash and cash equivalents of $20.5 million and marketable securities of $89.5 million as of June 30, 2026. The company raised capital through an at-the-market equity program and received $15.0 million from a royalty purchase agreement with Ligand and $20.0 million from a convertible loan from Medtronic. These arrangements created significant long-term obligations, including a $34.6 million royalty liability and a $20.4 million Medtronic note. Stockholders’ equity declined to $19.3 million, reflecting the ongoing accumulated deficit of $407.0 million, though management states available cash and investments are sufficient to fund operations for at least one year after issuance.
Orchestra BioMed Holdings, Inc. reported a Q1 2026 net loss attributable to common stockholders of $20.7 million, or $0.33 per share, compared with a $18.8 million loss a year earlier.
Total revenue fell to $0.1 million, primarily from product sales, after partnership revenue dropped to zero from $0.7 million. Operating expenses increased to $22.2 million, driven by higher research and development spending of $15.8 million and selling, general and administrative costs of $6.4 million.
At March 31, 2026, the company held $28.4 million in cash and cash equivalents and $66.0 million in marketable securities, with total assets of $100.7 million and stockholders’ equity of $41.2 million. Management states that existing cash, securities and contractual financing commitments are sufficient to fund operations for at least one year after the financial statements’ issuance date.
Orchestra BioMed (OBIO) reported Q3 2025 results with total revenue of $861 thousand (partnership $721 thousand; product $140 thousand) and a net loss of $20.8 million. Operating expenses were $21.2 million, driven by research and development of $14.0 million and selling, general and administrative of $7.1 million.
Liquidity improved during the period. Cash and cash equivalents were $42.0 million and marketable securities were $53.8 million as of September 30, 2025. Financing cash inflows totaled $75.7 million for the nine months, including $57.8 million net from a private placement and $20.0 million from a royalty purchase agreement. A related royalty liability of $16.2 million was recorded. Loan payable was $14.2 million. Deferred revenue was $13.3 million, reflecting the Terumo collaboration balance.
Partnership updates: the company amended its Medtronic agreement on August 4, 2025 to include a framework for AVIM-therapy integration into a dual‑chamber leadless pacemaker. On October 24, 2025, the Terumo agreement for Virtue SAB was terminated under a termination and right of first refusal agreement. Shares outstanding were 56,464,731 as of November 6, 2025.
Orchestra BioMed Holdings, Inc. reported a net loss of $19.4 million for the three months ended June 30, 2025 and $38.1 million year-to-date, compared with $16.0 million and $29.4 million in the prior-year periods. Total revenue remained modest at $0.836 million for the quarter, driven by partnership and product sales, while research and development expense rose to $13.9 million in the quarter as the company advances multiple clinical programs.
On the balance sheet, cash and cash equivalents totaled $18.7 million and marketable securities $15.2 million, giving total assets of $42.8 million versus $76.2 million at year-end 2024. Stockholders' equity declined to $0.3 million. Operating cash used was $32.1 million for the six months ended June 30, 2025. Deferred revenue from the Terumo collaboration was $14.0 million, with approximately $4.5 million expected to be recognized in the next 12 months. Management states available capital (including subsequent proceeds) is sufficient to fund operations through at least one year from issuance.